Friday, December 9, 2022


Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409

Lyvgen Biopharma, a leading innovative global biotech company dedicated to discovering, developing and commercializing first-in-class and best-in-class biotherapeutics for cancer, announced an open label,...

Biocytogen Enters into Antibody Agreement with ADC Therapeutics

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC...

Chemotherapy May Be Completed Within 8 Days With Two Doses of Polytaxel, Anticancer Drug From South Korea’s Biotech Firm

An innovative anticancer therapy that may complete chemotherapy with two doses of an anticancer drug in as short as 8 days is to enter...

Hemispherian raises the first tranche of a Series A to fund the development of its novel cancer therapeutics

Hemispherian AS, a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure...

Read Magazine’s Weekly News Roundup Featuring Draganfly Inc., Quaint Oak Bank, Domino’s, Cenntro and More!

Here is Read Magazine’s Weekly Roundup of the top news from global markets. In this fast paced world, breaking down information helps readers grasp...

Hot Topics